AbstractBackground. Chordomas are locally aggressive notochordal tumors with no systemic therapy options. As an ultra-rare cancer type, our understanding o

To evaluate KIF18A inhibitors as a potential therapeutic target, chordoma cell lines were treated with sovilnesib. A panel of four chordoma cell lines was seeded in a white-walled 96-well plate so tha...

Posted 12:34:07 PM. The Chordoma Foundation is seeking an experienced and high-agency individual to support the…See this and similar jobs on LinkedIn.

The aim of this research was to investigate the pathogenesis of the bone cancer chordoma and the role of the germline rs2305089 SNP in TBXT. Using medical imaging and genotyping studies, we observed ....

Make history in drug discovery

Make history in drug discovery

Make history in drug discovery

Paul Workman has researched untreatable chordoma for years. Now new technology points towards to a potential drug to beat it

TBXT, also called Brachyury, is a key driver and genetic dependency of chordoma, and is associated with disease progression in various other tumor types.…

Make history in drug discovery

This study describes structures of the transcription factor brachyury revealing the mechanism of DNA recognition. They identify fragments using X-ray fragment screening and optimize these into potent ...

Make history in drug discovery

Make history in drug discovery

Make history in drug discovery

This was Chordoma Foundation Labs' first invited oral presentation at a major professional conference, and our two posters won recognition as best in…

(A.) Treatment regime diagram. Cells were treated in 4 groups. Treatment additions are represented as colored circles. Combination treatment additions were administered 24 hours after the first treatm...

A panel of 4 chordoma cell lines was plated in a white-walled 96-well plate to evaluate response to azenosertib, a WEE1 kinase inhibitor, as a single agent treatment and azenosertib with gemcitabine a...

(A.) Treatment regime diagram. Cells were treated in 4 groups. Combination treatment additions were administered 24 hours after the first treatment addition. Due to doubling times and drug effects, ce...

(A. and B.) UM-Chor1, U-CHCF365, CH22, U-CH17PII, UM-Chor5D, and U-CH2 cells were plated in a white-walled 96-well plate to evaluate the synergistic effect between gemcitabine and ATR inhibition. The ...